Key Insights

Highlights

Success Rate

96% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.7%

2 terminated out of 290 trials

Success Rate

96.2%

+9.7% vs benchmark

Late-Stage Pipeline

6%

18 trials in Phase 3/4

Results Transparency

4%

2 of 50 completed with results

Key Signals

2 with results96% success

Data Visualizations

Phase Distribution

210Total
Not Applicable (38)
Early P 1 (3)
P 1 (40)
P 2 (111)
P 3 (13)
P 4 (5)

Trial Status

Recruiting106
Unknown66
Completed50
Not Yet Recruiting43
Active Not Recruiting15
Withdrawn3

Trial Success Rate

96.2%

Benchmark: 86.5%

Based on 50 completed trials

Clinical Trials (290)

Showing 20 of 20 trials
NCT07499128Not ApplicableNot Yet Recruiting

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

NCT05515796Phase 2CompletedPrimary

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

NCT06768931Phase 2Recruiting

Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer

NCT07062055Phase 2Recruiting

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases

NCT06935890Phase 4Recruiting

Jack Jumper Ant Venom Immunotherapy Long-term Effectiveness Investigation

NCT07475403Phase 2Recruiting

Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

NCT06985485Phase 2Recruiting

Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy

NCT06738160Phase 2Recruiting

The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer

NCT05848011Phase 2Active Not Recruiting

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07359040Active Not Recruiting

Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

NCT07458529Phase 2Recruiting

Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer

NCT07461675Phase 3Not Yet Recruiting

Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection

NCT03042156Completed

Immunotherapy And Palliative Radiotherapy Combined In Patients With Advanced Malignancy

NCT07280715Not ApplicableNot Yet Recruiting

Investigating Real-Time Immunotherapy Symptoms Study

NCT07291921Recruiting

To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)

NCT07436845Recruiting

Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy

NCT07409844Phase 2Not Yet Recruiting

Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer

NCT07113275Phase 3Not Yet Recruiting

A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer

NCT07396116Not ApplicableNot Yet Recruiting

Preoperative Hypofractionated RT + Immunotherapy & Surgery for Retroperitoneal Sarcoma (FUSION-02)

NCT06964568Phase 3Recruiting

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

Scroll to load more

Research Network

Activity Timeline